These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3196505)

  • 1. Long-term CaCO3 treatment of chronic hemodialysis patients: an attempt to prevent aluminum osteopathy.
    Matsubara M; Unagami H; Totsune K; Sato H; Kikuta Y; Ogawa M; Saito T; Yoshinaga K
    ASAIO Trans; 1988; 34(3):168-71. PubMed ID: 3196505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
    Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
    Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
    Anelli A; Brancaccio D; Damasso R; Padovese P; Gallieni M; Garella S
    Nephron; 1989; 52(2):125-32. PubMed ID: 2500612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.
    Jespersen B; Jensen JD; Nielsen HK; Lauridsen IN; Andersen MJ; Poulsen JH; Gammelgaard B; Pedersen EB
    Nephrol Dial Transplant; 1991; 6(2):98-104. PubMed ID: 1857534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
    Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients.
    Oettinger CW; Oliver JC; Macon EJ
    J Am Soc Nephrol; 1992 Oct; 3(4):995-1001. PubMed ID: 1450373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis.
    Okada K; Takahashi S; Nagura Y; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Oct; 31(10):1085-9. PubMed ID: 2615019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of calcium carbonate as a phosphate binder in dialysis patients.
    Hercz G; Kraut JA; Andress DA; Howard N; Roberts C; Shinaberger JH; Sherrard DJ; Coburn JW
    Miner Electrolyte Metab; 1986; 12(5-6):314-9. PubMed ID: 3807829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder.
    Ben Hamida F; el Esper I; Compagnon M; Morinière P; Fournier A
    Nephron; 1993; 63(3):258-62. PubMed ID: 8446261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism.
    Slatopolsky E; Weerts C; Norwood K; Giles K; Fryer P; Finch J; Windus D; Delmez J
    Kidney Int; 1989 Nov; 36(5):897-903. PubMed ID: 2615197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of high CaCO3 supplements on serum calcium and phosphorus in patients on regular hemodialysis treatment.
    Gonella M; Calabrese G; Vagelli G; Pratesi G; Lamon S; Talarico S
    Clin Nephrol; 1985 Sep; 24(3):147-50. PubMed ID: 4042444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
    Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia].
    Djerad M; Morinière P; Westeel PF; el Esper N; Boitte F; Morsli R; Schenouda M; Compagnon M; Achard JM; Fournier A
    Nephrologie; 1991; 12(4):193-7. PubMed ID: 1745337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
    Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
    Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium carbonate as a phosphate binder in children on continuous ambulatory peritoneal dialysis and hemodialysis.
    Sieniawska M; Roszkowska-Blaim M; Weglarska J; Jabłczyńska A; Welc-Dobies J
    Mater Med Pol; 1991; 23(3):203-8. PubMed ID: 1842716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral calcium carbonate administration ameliorates the progression of renal failure in rats with hypertension.
    Nakamura M; Suzuki H; Ohno Y; Ohishi A; Yamakawa H; Okada H; Saruta T
    Am J Kidney Dis; 1995 Jun; 25(6):910-7. PubMed ID: 7771488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.